Skip to main content
. 2022 Jun 24;127(6):1026–1033. doi: 10.1038/s41416-022-01887-3

Fig. 1. CCL23 is elevated in plasma and ascites from patients with ovarian cancer.

Fig. 1

a CCL23 levels in plasma from healthy donors (n = 40) and patients with HGSC (n = 25). b CCL23 levels in ascites samples from patients (n = 17) with HGSC. c Comparison of mean CCL23 levels in plasma from healthy donors, plasma from patients with HGSC and ascites samples from patients with HGSC. Each data point represents one patient sample. P values were calculated using Tukey’s multiple comparisons test (****P < 0.0001). d Kaplan–Meier survival analysis (log-rank test) of CCL23 expression in HGSC tumours and on survival of patients with ovarian cancer.